Genaera begins more squalamine trials

Genaera Corp. will begin three phase II trials on squalamine, its systemically administered anti-angiogenic drug.

Related Content:

Pharmacy

Investigators zoom in on future of dry eye treatment

Visus CEO updates on lead product candidate, 2021 pipeline

Analyzing opioid prescription patterns of US retina specialists